Target intelligence / Profile preview

Early secretory antigenic target 6 kDa (ESAT-6) (ESAT-6)

Target
ESAT-6
Molecular classification
Bacterial protein, Virulence factor, Secreted effector protein, WXG100 family protein
01

Overview

Early secretory antigenic target 6 kDa (ESAT-6) is a potent T-cell antigen produced by Mycobacterium tuberculosis and is a key virulence factor secreted via the ESX-1 secretion system (UniProt: P9WNK5). It plays a critical role in the pathogenesis of tuberculosis by facilitating the escape of the bacteria from the phagosome into the cytosol of host macrophages, thereby promoting intracellular survival and spread. Because ESAT-6 is present in virulent M. tuberculosis but absent in the vaccine strain Bacillus Calmette-Guérin (BCG), its antigenic epitopes are highly specific targets for diagnostic assays like Interferon-Gamma Release Assays (IGRAs). In therapeutic development, ESAT-6 epitopes are incorporated into subunit vaccines designed to boost or replace BCG-induced immunity by eliciting a robust Th1-mediated immune response. These epitopes are recognized by both CD4+ and CD8+ T-cells, making them central to modern tuberculosis vaccine strategies and diagnostic differentiation between infected and vaccinated individuals. The protein also interacts with host cell receptors such as Toll-like receptor 2 (TLR2), modulating the host's innate immune response to favor persistent infection. Furthermore, ESAT-6 forms a 1:1 heterodimer with CFP-10, which is essential for its stability and secretion.

Other names
EsxA6 kDa early secretory antigenic targetRv3875Antigen AS6Early soluble antigen target 6
02

Mechanism of action

Induction of cell-mediated immunity through the presentation of epitopes on MHC molecules to T-lymphocytes, triggering IFN-gamma release and macrophage activation.

03

Biological functions

Immune responsePhagosomal escapeCell lysisVirulenceT-cell activationMembrane disruption
04

Disease associations

InfectionTuberculosis
05

Safety considerations

Injection site reactionsKoch phenomenonHLA-linked non-responsivenessPotential for immune evasion via epitope mutation
06

Interacting drugs

4 more in the full profile.

07

Biomarkers

Interferon-gamma (IFN-γ)ESAT-6 specific T-cellsESAT-6 antibodies

Source types: Peer-reviewed publication. Sources are available to Gosset users. Log in to see them.

Beyond the preview

Go deeper on Early secretory antigenic target 6 kDa (ESAT-6) (ESAT-6).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Early secretory antigenic target 6 kDa (ESAT-6) (ESAT-6).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call